Co-Diagnostics Inc (NASDAQ:CODX)’s share price shot up 14.6% on Monday . The stock traded as high as $1.03 and last traded at $1.02, 226,132 shares changed hands during mid-day trading. A decline of 65% from the average session volume of 653,020 shares. The stock had previously closed at $0.89.

Several brokerages have weighed in on CODX. Zacks Investment Research cut shares of Co-Diagnostics from a “hold” rating to a “sell” rating in a research note on Thursday. HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of Co-Diagnostics in a research note on Friday, November 15th. Finally, Maxim Group set a $2.00 price objective on shares of Co-Diagnostics and gave the stock a “buy” rating in a research note on Thursday, September 5th.

The firm’s 50 day simple moving average is $0.97 and its two-hundred day simple moving average is $1.00.

Co-Diagnostics (NASDAQ:CODX) last issued its quarterly earnings data on Wednesday, November 13th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Co-Diagnostics had a negative return on equity of 202.74% and a negative net margin of 5,486.08%. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.10 million. Equities research analysts expect that Co-Diagnostics Inc will post -0.35 earnings per share for the current year.

Institutional investors have recently modified their holdings of the business. Barclays PLC raised its stake in Co-Diagnostics by 294.3% in the 3rd quarter. Barclays PLC now owns 72,950 shares of the company’s stock worth $75,000 after purchasing an additional 54,450 shares in the last quarter. HighTower Advisors LLC raised its stake in Co-Diagnostics by 13.0% in the 2nd quarter. HighTower Advisors LLC now owns 130,002 shares of the company’s stock worth $107,000 after purchasing an additional 15,000 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Co-Diagnostics by 142.1% in the 2nd quarter. Vanguard Group Inc. now owns 340,175 shares of the company’s stock worth $281,000 after purchasing an additional 199,685 shares in the last quarter. Institutional investors and hedge funds own 5.07% of the company’s stock.

Co-Diagnostics Company Profile (NASDAQ:CODX)

Co-Diagnostics, Inc, a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc was founded in 2013 and is headquartered in Salt Lake City, Utah.

Featured Article: Straddles

Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.